• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Changes of clinical symptoms in patients with new psychoactive substance (NPS)-related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction.2012财年至2014年新精神活性物质(NPS)相关障碍患者临床症状的变化:一项在成瘾治疗专科医院的研究。
Neuropsychopharmacol Rep. 2019 Jun;39(2):119-129. doi: 10.1002/npr2.12053. Epub 2019 Apr 9.
2
Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014.日本新型精神活性物质相关障碍患者临床特征的近期变化:2012 年和 2014 年全国精神卫生机构药物相关精神障碍调查的比较。
Psychiatry Clin Neurosci. 2016 Dec;70(12):560-566. doi: 10.1111/pcn.12434. Epub 2016 Sep 29.
3
Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.被诊断患有精神活性物质所致精神和行为障碍(F11 - 19 章)的精神科住院患者的特征,重点关注新型精神活性物质和精神科共病情况。
Int J Occup Med Environ Health. 2020 Mar 13;33(2):125-136. doi: 10.13075/ijomeh.1896.01495. Epub 2020 Jan 16.
4
The influence of tightening regulations on patients with new psychoactive substance-related disorders in Japan.日本加强监管对新型精神活性物质相关障碍患者的影响。
Neuropsychopharmacol Rep. 2018 Dec;38(4):189-196. doi: 10.1002/npr2.12035. Epub 2018 Oct 19.
5
Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data.新精神活性物质使用障碍在针对“药妆店”的立法后下降:来自国家成瘾治疗数据的证据。
Drug Alcohol Rev. 2017 Sep;36(5):609-617. doi: 10.1111/dar.12527. Epub 2017 Apr 16.
6
Legislation targeting head shops selling new psychoactive substances and changes in drug-related psychiatric admissions: A national database study.针对销售新精神活性物质的“摇头丸”店的立法和与毒品相关的精神科住院人数的变化:一项全国性数据库研究。
Early Interv Psychiatry. 2020 Feb;14(1):53-60. doi: 10.1111/eip.12807. Epub 2019 Apr 4.
7
Acute neurological consequences of novel psychoactive substance use: a retrospective review in a large UK hospital.新型精神活性物质使用的急性神经学后果:英国一家大型医院的回顾性研究
Clin Med (Lond). 2021 May;21(3):189-194. doi: 10.7861/clinmed.2020-0706. Epub 2021 May 4.
8
Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.2007年至2015年东北亚新型精神活性物质的流行情况。
Forensic Sci Int. 2017 Mar;272:1-9. doi: 10.1016/j.forsciint.2016.10.010. Epub 2016 Oct 20.
9
New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.新型精神活性物质(NPS)——成瘾治疗服务面临的一项挑战。
Pharmacopsychiatry. 2017 May;50(3):116-122. doi: 10.1055/s-0043-102059. Epub 2017 Apr 25.
10
New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.新型精神活性物质:欧洲应对其使用及危害的当前健康相关做法与挑战
Int J Drug Policy. 2017 Feb;40:84-92. doi: 10.1016/j.drugpo.2016.10.004. Epub 2016 Dec 9.

引用本文的文献

1
Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.年轻合成大麻素滥用者的急性肾损伤
Biomedicines. 2022 Aug 10;10(8):1936. doi: 10.3390/biomedicines10081936.

本文引用的文献

1
Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.2007年至2015年东北亚新型精神活性物质的流行情况。
Forensic Sci Int. 2017 Mar;272:1-9. doi: 10.1016/j.forsciint.2016.10.010. Epub 2016 Oct 20.
2
New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.新型精神活性物质:欧洲应对其使用及危害的当前健康相关做法与挑战
Int J Drug Policy. 2017 Feb;40:84-92. doi: 10.1016/j.drugpo.2016.10.004. Epub 2016 Dec 9.
3
Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014.日本新型精神活性物质相关障碍患者临床特征的近期变化:2012 年和 2014 年全国精神卫生机构药物相关精神障碍调查的比较。
Psychiatry Clin Neurosci. 2016 Dec;70(12):560-566. doi: 10.1111/pcn.12434. Epub 2016 Sep 29.
4
A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan.2013年至2014年日本对食用含新型精神活性物质产品后中毒情况的多中心回顾性调查。
Am J Drug Alcohol Abuse. 2016 Sep;42(5):513-519. doi: 10.1080/00952990.2016.1176177. Epub 2016 Jun 17.
5
New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015.2010 - 2015年澳大利亚常规精神刺激药物使用者中新精神活性物质的使用情况。
Drug Alcohol Depend. 2016 Apr 1;161:110-8. doi: 10.1016/j.drugalcdep.2016.01.024. Epub 2016 Feb 3.
6
Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.2011年至2014年向纽约市中毒控制中心报告的新型精神活性物质暴露特征。
Am J Drug Alcohol Abuse. 2016;42(1):39-47. doi: 10.3109/00952990.2015.1106551. Epub 2015 Dec 17.
7
Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.在美国一项具有全国代表性的调查中自我报告的新型精神活性物质使用情况:患病率、相关因素以及对防止漏报的新调查方法的呼吁。
Drug Alcohol Depend. 2015 Nov 1;156:112-119. doi: 10.1016/j.drugalcdep.2015.08.028. Epub 2015 Sep 3.

2012财年至2014年新精神活性物质(NPS)相关障碍患者临床症状的变化:一项在成瘾治疗专科医院的研究。

Changes of clinical symptoms in patients with new psychoactive substance (NPS)-related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction.

作者信息

Funada Daisuke, Matsumoto Toshihiko, Tanibuchi Yuko, Kawasoe Yasunari, Sakakibara Satoru, Naruse Nobuya, Ikeda Shunichiro, Sunami Takashi, Muto Takeo, Cho Tetsuji

机构信息

National Center of Neurology and Psychiatry, National Center Hospital, Kodaira, Japan.

National Center of Neurology and Psychiatry, National Institute of Mental Health, Kodaira, Japan.

出版信息

Neuropsychopharmacol Rep. 2019 Jun;39(2):119-129. doi: 10.1002/npr2.12053. Epub 2019 Apr 9.

DOI:10.1002/npr2.12053
PMID:30968601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7292321/
Abstract

AIMS

The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have focused on tightening regulation rather than establishing treatment methods. The current study sought to compare the neuropsychiatric symptoms of patients with NPS-related disorders across several years. We examined patients who attended specialized hospitals for treating addiction, to elucidate the impacts of legal measures to control NPS.

METHODS

Subjects (n = 864) were patients with NPS-related disorders who received medical treatment at eight specialized hospitals for treating addiction in Japan between April 2012 and March 2015. Clinical information was collected retrospectively from medical records.

RESULTS

Among psychiatric symptoms, the ratio of hallucinations/delusions decreased over time across 3 years of study (first year vs second year vs third year: 40.1% vs 30.9% vs 31.7%, P = 0.037). Among neurological symptoms, the ratio of coma/syncope increased over the 3-year period (7.8% vs 11.0% vs 17.0%, P = 0.002), as did the ratio of convulsions (2.8% vs 4.3% vs 9.7%, P = 0.001).

CONCLUSION

The symptoms associated with NPS were primarily psychiatric in the first year, while the prevalence of neurological symptoms increased each year. The risk of death and the severity of symptoms were greater in the third year compared with the first year, as regulation of NPS increased.

摘要

目的

在过去十年中,新型精神活性物质(NPS)在日本及国际上的使用日益广泛。NPS与一系列日益严重的临床、公共和社会问题相关。日本改善NPS影响的政治措施主要集中在加强监管而非建立治疗方法。本研究旨在比较数年间NPS相关障碍患者的神经精神症状。我们对前往专门治疗成瘾的医院就诊的患者进行了检查,以阐明控制NPS的法律措施的影响。

方法

研究对象(n = 864)为2012年4月至2015年3月期间在日本八家专门治疗成瘾的医院接受治疗的NPS相关障碍患者。临床信息通过回顾病历进行收集。

结果

在精神症状方面,幻觉/妄想的比例在3年的研究期间随时间下降(第一年 vs 第二年 vs 第三年:40.1% vs 30.9% vs 31.7%,P = 0.037)。在神经症状方面,昏迷/晕厥的比例在3年期间有所增加(7.8% vs 11.0% vs 17.0%,P = 0.002)、抽搐的比例也增加了(2.8% vs 4.3% vs 9.7%,P = 0.001)。

结论

与NPS相关的症状在第一年主要是精神方面的,而神经症状的患病率逐年增加。与第一年相比,随着对NPS监管的加强,第三年的死亡风险和症状严重程度更高。